# A Phase III, Randomized, Clinical Trial of GnP Combined With SBRT and Serplulimab Versus GnP as First-Line Treatment for Patients With Recurrent or Metastatic Pancreatic Cancer (WGOG-PAN 006/ICSBR-2)

> **NCT07336953** · PHASE3 · NOT_YET_RECRUITING · sponsor: **West China Hospital** · enrollment: 198 (estimated)

## Conditions studied

- PDAC - Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** GnP
- **RADIATION:** SBRT
- **DRUG:** Serplulimab

## Key facts

- **NCT ID:** NCT07336953
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02
- **Primary completion:** 2027-07
- **Final completion:** 2028-07
- **Target enrollment:** 198 (ESTIMATED)
- **Last updated:** 2026-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07336953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07336953, "A Phase III, Randomized, Clinical Trial of GnP Combined With SBRT and Serplulimab Versus GnP as First-Line Treatment for Patients With Recurrent or Metastatic Pancreatic Cancer (WGOG-PAN 006/ICSBR-2)". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT07336953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*